Shaily Engineering Plastics Releases Q4FY26 Earnings Call Transcript
Shaily Engineering Plastics released its Q4FY26 earnings call transcript. The company achieved commercial launch of pen injectors for Semaglutide in Canada and tentative US approval. It also entered semiconductor supply chain. For FY26, revenue grew 26% to ₹991 crore, PAT rose 83% to ₹170 crore. An enabling resolution to raise ₹500 crore was approved.
The announcement details significant strategic advancements, including new product commercializations in critical healthcare markets (Semaglutide in Canada and US), entry into the semiconductor supply chain, and strong financial performance with substantial PAT growth. These developments are expected to have a material positive impact on the company's future revenue streams and market positioning.
The company reported strong financial growth, successful product launches in regulated markets (Canada, tentative US approval for Semaglutide), entry into new high-growth sectors like semiconductors, and a positive outlook for key segments like Healthcare. The approval for a fundraise further indicates preparedness for future growth opportunities.
Shaily Engineering Plastics Limited (SHAILY) has released the transcript of its earnings conference call held on May 20, 2026, to discuss the company's operational and financial performance for the quarter and year ended March 31, 2026. The transcript is available on the company's website and was submitted to the BSE and NSE on May 27, 2026.
During the call, the management highlighted significant achievements, including the commercial launch of Shaily Harmony and Shaily Neo pen injectors for Semaglutide with multiple customers in India and global markets. The company's pen injectors have successfully launched in the Canadian market, marking an entry into a highly regulated pharmaceutical market. Additionally, Shaily's pen and its customer have received tentative approval in the U.S. market for Semaglutide, and a customer received European market authorization for Teriparatide.
The company also commenced commercial supplies to a consumer electronics customer, marking a new growth vector. Shaily has entered the semiconductor supply chain by signing a supply agreement with a Korean company for semiconductor trays. New business confirmations were received for power tool and LED light components in the industrial vertical.
The Board of Directors has approved an enabling resolution to raise up to ₹500 crores to maintain financial flexibility for seizing growth opportunities. The Healthcare segment was a standout performer, with revenue doubling in Q4 FY26 and surging 139% for the full year, contributing 40% of consolidated revenue. The Consumer segment saw a de-growth of 9% for the full year due to weaker market demand, while the Industrial segment grew 41% for the full year.
Consolidated revenue for Q4 FY26 stood at ₹237 crores, a 9% year-on-year growth, with EBITDA at ₹69 crores (up 27%) and PAT at ₹40 crores (up 40%). For the full year FY26, revenue grew 26% to ₹991 crores, EBITDA grew 61% to ₹288 crores, and PAT grew 83% to ₹170 crores.
Looking ahead to FY27, priorities include scaling the healthcare vertical, building the Abu Dhabi facility, ramping up consumer electronics and semiconductor programs, and restoring growth in the consumer home furnishing segment. The company anticipates significant opportunities in healthcare and consumer electronics, followed by semiconductor and industrial/consumer segments.
What to do with a filing like this
Shaily Engineering Plastics Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shaily Engineering Plastics Limited. Read the original for the full detail.